Prednisone
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Prednisone: From Systemic Corticosteroid Therapy to Alopecia Areata
One-Sentence Summary
Prednisone is a systemic corticosteroid with broad, long-established use in autoimmune and inflammatory disease, though this evidence pack does not specify a UK-licensed original indication (data gap). The TxGNN model predicts it may be effective for Alopecia Areata, with 1 directly relevant randomised controlled trial and 10 supporting publications currently identified — although the majority of clinical trials retrieved for this candidate were assessed as low-relevance background noise (drug co-occurrence in unrelated conditions such as SLE, lymphoma and prostate cancer).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in this evidence pack (data gap); prednisone is broadly used as a systemic glucocorticoid for autoimmune/inflammatory conditions |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (data gap). Based on known pharmacology, prednisone is a systemic glucocorticoid that suppresses T-cell-mediated immune activity — the central pathological mechanism believed to drive follicular autoimmune attack in alopecia areata (AA). Corticosteroids of this class have long been used empirically for autoimmune and inflammatory conditions generally, and this immunosuppressive action provides a direct, biologically plausible rationale for use in AA.
Clinically, systemic corticosteroids (including prednisone) are already an established adjunct or rescue option for moderate-to-severe AA in real-world dermatology practice, predating this prediction. This is reflected in a substantial body of literature spanning from the 1950s to 2024, including a 2023 double-blind randomised trial combining low-dose prednisone with methotrexate for the most severe AA subtypes (alopecia totalis/universalis).
However, the strongest RCT evidence available tests prednisone as a low-dose adjunct to methotrexate, not as monotherapy, and most retrieved clinical trials (predominantly in systemic lupus erythematosus, lymphoma and prostate cancer) reflect prednisone’s ubiquitous use as background standard-of-care rather than a direct test of efficacy in AA. This combination of a genuine but narrow evidence base is why the evidence level is rated L3 rather than higher.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT02037191 | Phase 3 | Completed | 90 | Randomised, double-blind multicentre trial testing methotrexate versus placebo (with secondary low-dose prednisone treatment) in severe alopecia areata; directly relevant to prednisone use in AA |
Note: A further ~30 trials referencing “prednisone” were returned by the search but were assessed as low relevance (grade C or unclassified) — these are predominantly systemic lupus erythematosus, non-Hodgkin/Hodgkin lymphoma and prostate cancer trials in which prednisone appears only as part of an unrelated background chemotherapy or standard-of-care regimen, not as a treatment being tested for alopecia areata. These have been excluded from the table above to avoid overstating the evidence base.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36884234 | 2023 | RCT | JAMA Dermatology | Two-step double-blind RCT: methotrexate alone vs methotrexate + low-dose prednisone in alopecia totalis/universalis |
| 1444509 | 1992 | Review | Archives of Dermatology | Review of AA therapies covering efficacy, safety and mechanism across treatment modalities including corticosteroids |
| 4571041 | 1973 | Cohort | Archives of Dermatology | Immunologic studies in AA with prednisone treatment |
| 791152 | 1976 | Cohort | Archives of Dermatology | Follow-up report on prednisone therapy for AA; initial response noted but limited long-term benefit and notable steroid side effects |
| 26735937 | 2016 | Cohort | Dermatology (Basel) | Efficacy and safety of methotrexate combined with low-to-moderate dose corticosteroids in severe AA |
| 13368875 | 1956 | Cohort | Medical Times | Early series treating AA partialis/totalis with cortisone, hydrocortisone, prednisone and prednisolone |
| 911178 | 1977 | Cohort | Archives of Dermatology | Prednisone therapy for alopecia areata |
| 38650498 | 2024 | Cohort | Italian Journal of Dermatology and Venereology | Real-world characterisation of hospitalised AA patients in Italy, including treatment patterns and comorbidities |
| 20804894 | 2010 | Uncategorised | Annales de Dermatologie et de Vénéréologie | Efficacy and safety of once-monthly oral pulsed prednisone in AA management |
| 8996277 | 1997 | Uncategorised | Journal of the American Academy of Dermatology | Systemic cyclosporine combined with low-dose prednisone in chronic severe AA, with clinical and immunopathologic evaluation |
UK Market Information
No UK marketing authorisation currently exists for prednisone within this evidence pack (0 licences on record; market status: Not Marketed).
For context, prednisone requires hepatic conversion to its active metabolite, prednisolone. In UK clinical practice, prednisolone (rather than prednisone) is the corticosteroid routinely marketed and prescribed for equivalent indications — this may explain the absence of a UK licence for prednisone itself.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications and drug interaction data were not available in this evidence pack (flagged as a Blocking data gap — see Conclusion).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: There is a genuine, mechanistically coherent, and long-standing body of clinical evidence (including one completed Phase 3 RCT and multiple decades of cohort experience) supporting glucocorticoid use in moderate-to-severe alopecia areata, but the strongest trial evidence tests prednisone only as a low-dose adjunct to methotrexate rather than as monotherapy, and formal safety/regulatory data are currently absent.
To proceed, the following is needed:
- TFDA/UK SmPC-equivalent warnings, contraindications and drug interaction data (Blocking gap — required before any S1 safety assessment)
- Detailed mechanism of action characterisation (High-priority gap)
- Clarification of the UK regulatory/access pathway, given prednisone itself holds no UK marketing authorisation (unlicensed use or prednisolone-based equivalence would need to be considered)
- A dosing/regimen review distinguishing monotherapy use from the combination (prednisone + methotrexate) regimen actually tested in the pivotal RCT
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.